Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | IGFBP3 | P17936 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590415 | 1.00 | TSPO (0.59) | TSPOKMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL10984073 | 0.87 | TSPO (0.47) | TSPOKMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL10987170 | 0.87 | TSPO (0.58) | TSPOKMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL15850566 | 0.87 | TSPO (0.61) | TSPOKMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL10990018 | 0.85 | KMT2A (0.50) | TSPOKMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL3035741 | 0.85 | KMT2A (0.46) | TSPOKMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL3434531 | 0.83 | TSPO (0.58) | TSPOKMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL8470659 | 0.82 | TSPO (0.59) | TSPOKMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL117174 | 0.82 | ADORA2A (0.48) | TSPOKMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL10982335 | 0.82 | CNR1 (0.56) | TSPOKMT2AMEN1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049839-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-02-13 | — | — | US | disclosed |
| US-12161663-B2 | Compositions and methods for targeting cells | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12161663-B2 | Compositions and methods for targeting cells | CD47, CD44, CX3CR1 | TSPO 33/4885KMT2A 3252/4885MEN1 2860/4885 |
| US-20250049839-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLS | CD47, CD44, CX3CR1 | TSPO 33/4885KMT2A 3252/4885MEN1 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.